An impairment of prefrontal cortical functioning in schizophrenia ('hypofrontality') has been suggested by clinical, neuroimaging, and postmortem brain tissue studies. We used Western immunoblot and Northern hybridization analyses of postmortem brain tissue obtained from 14 schizophrenic patients and 12 control patients of similar ages to measure tissue levels of synaptophysin (a structural synaptic vesicle protein) and of SNAP-25 (a 25-kDa presynaptic protein), and their encoding mRNAs, in Brodmann's area 10 of prefrontal cortex. There were significant decreases in tissue levels of both of these proteins in prefrontal cortex of schizophrenic patients relative to controls. In contrast, tissue levels for the mRNAs encoding these proteins were not decreased in schizophrenic patients. Subsequent labeling of the same Western immunoblots showed no difference in tissue levels of glial fibrillary acidic protein (GFAP) in schizophrenic and control patients. Similarly, subsequent hybridization of the same Northern hybridization membranes showed no difference in tissue levels of GFAP mRNA or of 28S rRNA in schizophrenic and control patients. These alterations in tissue levels of synaptophysin and SNAP-25 are consistent with the idea that the clinically observed 'hypofrontality' of schizophrenia arises from abnormalities of synaptic number or structural integrity in prefrontal cortex.
Introduction
Abnormalities of the frontal lobe in schizophrenic patients have been suggested by a variety of neuropsychological and neuroimaging techniques. 1, 2 For instance, schizophrenic patients show impaired performance on components of the Wisconsin Card Sort Test that are sensitive to frontal lobe function, 3, 4 and neuroimaging studies of schizophrenics have shown both reduced volume of prefrontal cortex and difficulties with prefrontal activation. [5] [6] [7] [8] Such suggestions of 'hypofrontality' in schizophrenia are not supported, however, by neuronal counting investigations, which have shown normal 9 or increased 10 neuronal density in prefrontal cortex of schizophrenic patients.
The contrasting findings of prefrontal dysfunction with normal or even increased neuronal density might be reconciled if there were a reduction in synaptic elements in the prefrontal cortex of schizophrenic patients. This possibility has received support from recent studies showing decreased immunoreactivity for synaptophysin-a synaptic vesicle-associated protein 11 -in tissue sections, 12 and from studies showing variable tissue levels of SNAP-25, 13 in frontal cortex of schizophrenics.
In this study, we used Western immunoblot analysis of autopsy tissue to directly measure tissue levels of two presynaptic terminal-associated proteins in prefrontal cortex of schizophrenic and control patients. In addition to synaptophysin, we analyzed the 25-kDa synaptosome-associated protein, SNAP-25, a component of the synaptic vesicle fusion complex. Both SNAP-25 and its mRNA have been localized to presynaptic terminals. 14, 15 We also determined the tissue levels of synaptophysin and SNAP-25 mRNA in prefrontal cortex of schizophrenic and control patients. Written informed consent was obtained from those patients who received premortem psychiatric assessment. Postmortem brain tissue was obtained from 26 patients: 14 of these (13 males; one female, 65 ± 12 (mean ± s.d.) years of age) were diagnosed with schizophrenia as described below; 12 (11 males; one female, 67 ± 8 years of age) were not schizophrenic, and died in our hospital from a variety of medical conditions (Table 1) . These latter were classified as controls. Neither brain weights nor postmortem intervals of controls (6 ± 4 h) were significantly different from those of schizophrenics (10 ± 6 h; P = 0.07 for PMIs). The psychiatric profiles and medication history of these patients are discussed below.
Materials and methods

Patients
One patient with schizophrenia was receiving cloza- ). Three patients with schizophrenia were not receiving antipsychotic medications at death, one was receiving atenolol (50 mg day −1 ), another diphenhydramine (dose uncertain) and one fluoxetine (40 mg day −1 ). Eight of the control patients were not receiving psychotropic medications at the time of death; one was receiving amitriptyline (50 mg day −1 ), one was receiving diazepam (10 mg day −1 ), and one was receiving mesoridazine (see below for explanation).
Psychiatric diagnosis
All schizophrenic patients were diagnosed as schizophrenic during life. These probable lifetime psychiatric diagnoses were confirmed for all patients using the Diagnostic Evaluation After Death. 16 This is a structured data review for which the main source of information is the medical record. In addition, six of our schizophrenic patients did receive detailed psychiatric evaluation during life, according to DSM-III-R criteria, by participating psychiatrists in our institution.
Three control patients had histories consistent with alcohol dependence. Two ceased consuming alcohol 8 and 10 years prior to death, while the third had ongoing difficulties with alcohol. One control patient had a long history of rheumatoid arthritis, treated since the early 1980s with oral fluphenazine, 2 mg day
, and amitriptyline, 50 mg at bedtime, to control pain. This had caused a tardive dyskinesia that required mesoridazine for control.
Neuropathological evaluation
The right cerebrum and right cerebellum were fixed by immersion for 10-14 days in 20% phosphate-buffered formalin. These were then sectioned for gross examination and extensively sampled for paraffin embedding and histological evaluation. In addition to hematoxylin and eosin staining of all sections, selected sections were stained with the Sevier-Munger modification of Bielschowski's stain for evaluation of senile changes (neuritic plaques and neurofibrillary tangles). None of the patients included in this study showed significant neuropathological changes. Mild 'senile' changes (normal for age) were present in seven patients (three schizophrenics and four controls) and small, preterminal embolic infarcts of the occipital cortex were present in two schizophrenic patients.
Dissection
Prefrontal cortex from the left brain of both control and schizophrenic patients was dissected fresh at the time of gross autopsy. Samples from Brodmann's area 10 (frontal pole) were defined by taking the portion of brain rostral to a vertical cut 2 cm posterior to the apex of the frontal pole and superior to the orbitofrontal gyrus. Full thickness cortical samples, dissected free of white matter, were allocated for Western and Northern analysis, quick frozen in liquid nitrogen, and stored at −85°C until used.
Tissue preparation
Total DNA, RNA, and proteins were extracted from cerebral cortex using TriReagent TM (Molecular Research Center, Cincinnati, OH, USA). Tissue samples, flash frozen in liquid nitrogen at the time of autopsy, were stored at −85°C until homogenization and extraction. Each sample (approximately 250 mg) was homogenized in 1 ml of TriReagent, and subsequent separation of total DNA, total RNA, and total protein was performed according to manufacturer's instructions.
Western immunoblot analysis
Samples containing 20 g of protein were subjected to 10% sodium-dodecyl-sulfate (SDS) polyacrylamide gel electrophoresis at 150 V for 40 min and then transferred, at 76 V for 30 min, to nitrocellulose membranes. Samples from all of the 14 schizophrenic and 12 control patients included in this study were run simultaneously on a total of four gels. The membranes were incubated with monoclonal anti-SNAP-25 antibody (1:1000; Sternberger Monoclonals, Baltimore, MD, USA), followed by incubation with 125 I-labelled goat anti-mouse IgG (1 Ci) for 1 h, and then exposed to Kodak XAR film for 3 days. These same membranes were subsequently reprobed with monoclonal anti-synaptophysin antibody (ICN, Biomedical, Costa Mesa, CA, USA) diluted 1:50 for 1 h, and later with rabbit polyclonal anti-bovine glial fibrillary acidic protein (GFAP) antibody (DAKO, Carpinteria, CA, USA), diluted 1:1500 for 24 h, followed by incubation with either 125 I-labelled goat-anti-mouse IgG (1 Ci) or 125 Ilabelled goat-anti-rabbit IgG (1 Ci), respectively, for 1 h and then exposed to Kodak XAR film for 3 days. For quantitative analysis of SNAP-25, synaptophysin, and GFAP, the autoradiographic images were scanned (Mirror Inc, Edina, MN, USA) into an Adobe Photoshop (Mountain View, CA, USA) program on a Macintosh Power PC 8500 from which they were captured into the NIH Image Analysis Program, version 1.60b7. Linearity of staining was validated using standards for bovine serum albumin, GFAP, and synaptophysin. Image background was subtracted so that the images could be calibrated. Densitometric analyses were performed blind to clinical diagnosis. Units were expressed as absorbance intensity g −1 protein.
Northern analysis
We probed for synaptophysin RNA (human cDNA was obtained from American Type Culture Collection, Rockville, MD, USA), for SNAP-25 RNA (human cDNA was received as a gift from Dr Michael Wilson, University of New Mexico), and for GFAP RNA and 28S RNA (human cDNA was obtained from American Type Culture Collection). Equal amounts (10 g) of total RNA from each sample, extracted as above, were subjected to electrophoresis on a 1.0% agarose, 2% formaldehyde gel, and then transferred to a Zeta-probe TM membrane (BioRad Laboratories, Hercules, CA, USA) by capillary action over a 12-h period, using 10 × SSC (87 g L
NaCl, 44 g L −1 sodium citrate, pH 7.0). RNA from four schizophrenics and two controls was degraded and was not used for further analysis. The remaining samples from 10 schizophrenics (nine males: one female, 65 ± 14 (mean ± s.d.) years of age; postmortem interval 11 ± 7 h) and 10 controls (nine males; one female, 68 ± 7 years of age; postmortem interval 6 ± 4 h) were used for Northern analysis. The membranes were fixed in 0.05 N NaOH for 5 min at room temperature, prehybridized for 2 h, then hybridized overnight with 5 mg ml −1 bovine serum albumin (Calbiochem, San Diego, CA, USA), 10 mM EDTA, 0.5 mM NaPO 4 and 3% SDS. Hybridization was performed at 65°C for 16 h using 32 P-labeled human synaptophysin, SNAP-25, GFAP, or 28S cDNAs. cDNAs were labelled to high specific activity (1 × 10 9 cpm g −1 cDNA) with 32 P-labelled d-CTP using a random primer labeling kit (Ambion, Austin, TX, USA). Membranes were washed in 0.04 NaPO 4 , pH 7.2, 5% SDS, 10 mM EDTA at 65°C for 40 min, then 0.04 NaPO 4 , pH 7.2, 1% SDS, 10 mM EDTA at 65°C for 40 min, and finally 1.6 × SSC, 0.1% SDS, 5 mM Tris HCl, pH 8.0, and 1 mM EDTA. Membranes were then exposed to RX Fuji X-ray film (Fisher, Dallas, TX, USA) for 10 days for synaptophysin or GFAP mRNA, 6 days for SNAP-25 mRNA, and 15 min for 28S rRNA, as previously described. 17 Autoradiographs were scanned using Mirrorscan software and analyzed using NIH Image software, version 1.60b7. Densitometric analyses were performed blind to clinical diagnosis. Units were expressed as absorbance intensity of specific mRNAs relative to absorbance intensity of 28S RNA.
Statistics
We analyzed for correlations (Spearman's test) between mRNA levels (synaptophysin, SNAP-25 and GFAP) and potential confounding factors (age, PMI, tissue storage interval, sex, and infectious vs non-infectious cause of death) and found no significant correlationsthe average P value for the 15 different calculations was 0.507, with the only P values less than 0.3 being 0.06 for GFAP vs sex and 0.07 for SNAP-25 vs age.
Statistical analysis for comparisons between schizophrenic and control samples was performed using the Mann-Whitney U Test. As Glantz and Lewis 12 have previously described reduced synaptophysin immunoreactivity in an adjacent region of prefrontal cortex, a one-tailed assumption was used to test for significance in the direction of a reduced level of either protein.
Results
An example of Western immunoblot analysis of prefrontal cortex extracts, sequentially immunolabelled for synaptophysin, SNAP-25, and GFAP, is shown in Figure 1 . Schizophrenic patients showed a significant decrease in the levels of synaptophysin in prefrontal (Brodmann's area 10) cortex relative to those in control patients (0.6 ± 0.2 vs 0.8 ± 0.2 (mean ± s.d.) absorbance units (AU), P Ͻ 0.05, Figure 2d) . Similarly, tissue levels of SNAP-25 in prefrontal cortical tissue from schizophrenic patients were decreased relative to con- trol values (0.2 ± 0.1 vs 0.4 ± 0.1 AU, respectively, P Ͻ 0.002, Figure 2f ). Across our patient population, tissue levels of SNAP-25 were significantly correlated with tissue levels of synaptophysin in prefrontal cerebral cortex (not shown).
In contrast, the levels of GFAP in prefrontal cortex of schizophrenic and control patients were not significantly different (1 ± 0.1 vs 0.9 ± 0.2 AU, P Ͼ 0.6, Figure  2b ). Neither synaptophysin, SNAP-25, nor GFAP levels showed any significant correlations with patient age, postmortem interval, or gross brain weight. Among these correlations, the only P values less than 0.3 were 0.06 for GFAP vs sex and 0.07 for SNAP-25 vs age. Northern analysis of prefrontal cortex (Figure 3 ) did not show decreased levels of synaptophysin mRNA relative to 28S RNA in schizophrenics compared to controls (1.2 ± 0.5 vs 0.4 ± 0.3 AU, respectively). Likewise, SNAP-25 mRNA levels were not decreased relative to 28S RNA in prefrontal cortex of schizophrenic patients relative to controls (2.5 ± 0.9 vs 1.0 ± 0.5 AU). GFAP mRNA levels were similar in schizophrenic and control patients (1.1 ± 0.5 vs 0.9 ± 0.6 AU). We found no significant correlations (ie no P values were less than 0.3) between mRNA levels determined here (viz, synaptophysin, SNAP-25, or GFAP) and the potentially confounding factors of patient age, postmortem interval, tissue storage interval, patient sex, and infectious vs non-infectious cause of death.
Discussion
We show significant decreases in tissue levels of two intrinsic synaptic proteins, synaptophysin and SNAP-25, in prefrontal cortex (Brodmann's area 10) of schizophrenic patients. In contrast, tissue levels of the encoding mRNAs for synaptophysin and SNAP-25 were not decreased. These neurochemical results are consistent with the idea 12 that schizophrenia is characterized by an abnormality of synaptic elements in prefrontal cortex. This abnormality might be a decrease in total synaptic elements or altered synaptic integrity. A decrease in total synaptic element number could be developmentally based or could result from a later-onset pathologic process that culls presynaptic elements in these patients. This possibility, however, would leave unexplained the normal or increased tissue levels of synaptophysin and SNAP-25 mRNAs in schizophrenia. Dissociation between synaptophysin protein and mRNA expression also occurs during embryonic development. 18 As an alternative possibility, altered synaptic integrity might result from changes in the number or size of synaptic vesicles (reflected in decreased synaptophysin levels), or changes in the synaptic vesicle fusion process (reflected in decreased SNAP-25 levels). Such alterations in intrasynaptic kinetics might result in compensatory increases in synaptophysin and SNAP-25 mRNA transcription in schizophrenics, as shown here. In either case, such synaptic abnormalities might underlie the 'hypofrontality' apparent in clinical and neuroimaging studies of schizophrenic patients. Such an abnormality of presynaptic elements in schizophrenia could also reconcile clinical dysfunction in the prefrontal cortex with normal or increased neuronal density 9, 10 in this area. Reversible decreases in synaptic density in subcortical structures have been observed in rats developing tardive dyskinesia-like behavioral changes during chronic haloperidol administration. 19 Because a substantial fraction of the patients with schizophrenia did have tardive dyskinesia, the issue of antipsychotic treatment affects bears further study. The decreases we find in synaptophysin and SNAP-25 levels in prefrontal cortex of schizophrenic patients are unlikely to be attributable to long-term treatment with antipsychotic medications, as prefrontal cortical tissue levels for synaptophysin and SNAP-25 were high (0.58 and 0.37 AU, respectively) for the one control patient who was receiving neuroleptic therapy at the time of death; and were low (0.30 and 0.21 AU, respectively) for the one schizophrenic patient who was not receiving antipsychotic medications at the time of his death. Indeed, the prefrontal cortical synaptophysin level for this latter patient is the lowest value recorded for any patient, schizophrenic or control, in this study. If active treatment with antipsychotic medications were responsible for the observed decreases in levels of these synaptic proteins, this result would be unlikely.
Three of our control patients had psychiatric diagnoses of alcohol dependence. Animal studies have suggested that chronic alcohol treatment may reduce syn- Figure 3 Northern hybridization and densitometric analysis of mRNAs using cDNAs for synaptophysin mRNA, for SNAP-25 mRNA, for GFAP mRNA, and for 28S rRNA in prefrontal (Brodmann's area 10) cortical tissue extracts from schizophrenic and control patients. aptic densities in cerebellum 20, 21 and in brainstem nuclei. 22 Such a confounding effect, however, would skew the present data toward lesser, rather than greater, differences between schizophrenic and control populations.
In summary, we find decreased levels of two intrinsic synaptic proteins, without decreases in levels of their encoding mRNAs, in prefrontal cortex (Brodmann's area 10) of schizophrenic patients. These data are consistent with the idea that alterations in prefrontal cortical synaptic elements may underlie the decrements in frontal lobe function in schizophrenic patients.
